This page summarizes the type of evidence that exists for dulaglutide. It is not a systematic review and does not cite specific trials.
Overview
Dulaglutide is a well-studied, approved GLP-1 receptor agonist. Its literature spans a structured clinical development program in type 2 diabetes, dedicated cardiovascular outcome research, and analyses of related metabolic endpoints. The maturity of that evidence is why its diabetes effects can be described with more confidence than more speculative claims.
Glycemic-control research
The core body of work established dulaglutide's effect on glycemic control in type 2 diabetes. Studies have examined:
- Reductions in average blood glucose as monotherapy and as add-on therapy.
- Comparisons with other glucose-lowering agents.
- Body-weight changes observed alongside glycemic endpoints.
Cardiovascular outcome research
A distinctive feature of dulaglutide's evidence base is dedicated cardiovascular outcome research examining major cardiovascular events in relevant populations. This type of study is what allows the class to be discussed in cardiovascular-risk terms rather than by glycemic effects alone, though relevance depends on baseline risk.
Other endpoints
Beyond glucose and cardiovascular endpoints, research has explored renal-related measures and weight, consistent with class-wide interest in the broader metabolic effects of GLP-1 receptor agonists. These areas continue to be investigated.
Context and caveats
Despite a substantial evidence base, several caveats apply. Findings are strongest for the approved product in its studied populations, not for vendor "research" material. When reviewing the literature, consider study design, endpoints, duration, and how closely the setting matches an individual's situation. Marketing narratives frequently move faster than the evidence supports.